Senate Dems Test Out 'Reasonable' Price Criteria With Antibiotic Incentive
Franken bill includes co-pay caps for new drugs but plenty of price control proposals, including a definition for reasonable price tied to an antibiotics prize.
You may also be interested in...
The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.
Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.
PhRMA ad campaign targets US payer practice of using drug rebate dollars for general premium and cost sharing reductions and not to lower the cost of specific prescription fills.